Compare PTCT & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTCT | HAE |
|---|---|---|
| Founded | 1998 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 4.8B |
| IPO Year | 2006 | 1996 |
| Metric | PTCT | HAE |
|---|---|---|
| Price | $63.51 | $120.98 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 11 |
| Target Price | $101.07 | ★ $122.20 |
| AVG Volume (30 Days) | ★ 1.2M | 605.0K |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 264.48 | N/A |
| EPS | ★ 0.90 | 0.72 |
| Revenue | $264,734,000.00 | ★ $910,373,000.00 |
| Revenue This Year | N/A | $6.27 |
| Revenue Next Year | $9.26 | $5.86 |
| P/E Ratio | ★ $71.38 | $165.10 |
| Revenue Growth | ★ 36.19 | N/A |
| 52 Week Low | $61.23 | $48.55 |
| 52 Week High | $90.87 | $121.19 |
| Indicator | PTCT | HAE |
|---|---|---|
| Relative Strength Index (RSI) | 40.49 | 77.14 |
| Support Level | $62.46 | $72.93 |
| Resistance Level | $72.86 | N/A |
| Average True Range (ATR) | 2.00 | 3.12 |
| MACD | 0.19 | 1.24 |
| Stochastic Oscillator | 38.57 | 98.90 |
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The Plasma segment includes end-to-end collection technologies, automated plasmapheresis systems (such as the NexSys PCS device), and donor management software designed for commercial plasma collectors. Hospital segment includes Blood Management Technologies (hemostasis analyzers, cell salvage systems) and Interventional Technologies. And the Blood Center provides solutions and devices enabling blood centers to harvest essential components like platelets and red blood cells.